Medivir AB (publ)
MVRBF
Other OTC0.82
USD
- -
- -
Return %
Stock
S&P500
1Y
-8.89
26.53
3Y
-8.89
76.60
5Y
-8.89
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jens Lindberg
- Full Time Employees
- 10
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Lunastigen 5 Huddinge Sweden
- IPO Date
- Jun 22, 2010
- Website
- medivir.com
- Similar Companies
- Business
- Medivir AB (publ) (Nasdaq Stockholm: MVIR B; OTC: MVRBF) is a Swedish biotechnology company that researches, develops and commercializes innovative pharmaceuticals with a primary focus on oncology to address high unmet medical needs. Founded in 1988 and headquartered in Huddinge, Sweden, the company advances a pipeline of proprietary and partnered drug candidates targeting liver cancer, cutaneous T-cell lymphoma, basal cell carcinoma, solid tumors, osteoarthritis and infectious diseases; key programs include fostroxacitabine bralpamide (fostrox), a selective oral nucleotide DNA polymerase inhibitor in Phase II for hepatocellular carcinoma (both monotherapy and in combination with lenvatinib), remetinostat for mycosis fungoides cutaneous T-cell lymphoma and basal cell carcinoma, MIV-818 for liver cancer, MIV-711 for osteoarthritis, birinapant and IGM-8444 (via partner IGM Biosciences) for solid tumors, as well as preclinical efforts like a USP7 inhibitor with Ubiquigent Limited and antivirals with INFEX Therapeutics; it also markets Xerclear (Zoviduo), a hydrocortisone-acyclovir combination for labial herpes. Medivir conducts operations globally through in-house development, clinical collaborations and partnerships with international pharmaceutical firms, leveraging clinical expertise and industry experience from its Nasdaq Stockholm Small Cap listing. In late 2025, the company completed a fully guaranteed rights issue raising SEK 151 million (net cash proceeds of SEK 133.7 million after debt offset to principal owner Linc), with underwriters DNB Carnegie and Zonda Partners covering one-third, to fund a randomized Phase IIb study of 30-50 patients per arm comparing fostrox plus lenvatinib to lenvatinib monotherapy in second-line advanced hepatocellular carcinoma, targeting accelerated approval by 2027; earlier, partner IGM Biosciences prioritized its pipeline in 2023, impacting the birinapant-aplitabart combination licensed from Medivir in 2021, while Medivir presented mature Phase Ib/IIa data for fostrox plus Lenvima at the 2025 ESMO conference in Barcelona confirming potential efficacy.
Medivir AB (publ) (MVRBF) Q4 2025 Earnings Call Transcript
Medivir AB (publ) (MVRBF) Q3 2025 Earnings Call Transcript
Medivir to present at the Pareto Securities Healthcare Conference
Change in Medivir's nomination committee before the 2024 AGM
Notice of Extraordinary General Meeting in Medivir AB (publ)
MEDIVIR AB - INTERIM REPORT JANUARY - SEPTEMBER 2023
MEDIVIR AB - INTERIM REPORT JANUARY - JUNE 2023
Medivir to present at the Redeye Fight Cancer Day